These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36715830)

  • 1. A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest.
    Balducci L; Falandry C; List A
    Drugs Aging; 2023 Mar; 40(3):263-272. PubMed ID: 36715830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
    Balducci L; Falandry C; List A
    Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle arrest: A breakthrough in the supportive care of older cancer patients.
    Falandry C; List A; Balducci L
    J Am Geriatr Soc; 2023 Jul; 71(7):2297-2307. PubMed ID: 37036091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
    Weiss JM; Csoszi T; Maglakelidze M; Hoyer RJ; Beck JT; Domine Gomez M; Lowczak A; Aljumaily R; Rocha Lima CM; Boccia RV; Hanna W; Nikolinakos P; Chiu VK; Owonikoko TK; Schuster SR; Hussein MA; Richards DA; Sawrycki P; Bulat I; Hamm JT; Hart LL; Adler S; Antal JM; Lai AY; Sorrentino JA; Yang Z; Malik RK; Morris SR; Roberts PJ; Dragnev KH;
    Ann Oncol; 2019 Oct; 30(10):1613-1621. PubMed ID: 31504118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
    Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
    Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
    Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
    Li C; Hart L; Owonikoko TK; Aljumaily R; Rocha Lima CM; Conkling PR; Webb RT; Jotte RM; Schuster S; Edenfield WJ; Smith DA; Sale M; Roberts PJ; Malik RK; Sorrentino JA
    Cancer Chemother Pharmacol; 2021 May; 87(5):689-700. PubMed ID: 33595690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
    Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
    Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
    Dómine Gómez M; Csőszi T; Jaal J; Kudaba I; Nikolov K; Radosavljevic D; Xiao J; Horton JK; Malik RK; Subramanian J
    Int J Cancer; 2021 Oct; 149(7):1463-1472. PubMed ID: 34109630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
    Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
    Abraham I; Onyekwere U; Deniz B; Moran D; Chioda M; MacDonald K; Huang H
    J Med Econ; 2021 Nov; 24(sup1):71-83. PubMed ID: 34873975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
    Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 14. Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
    Hussein M; Maglakelidze M; Richards DA; Sabatini M; Gersten TA; Lerro K; Sinielnikov I; Spira A; Pritchett Y; Antal JM; Malik R; Beck JT
    Cancer Manag Res; 2021; 13():6207-6218. PubMed ID: 34408488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis.
    Dai HR; Yang Y; Wang CY; Chen YT; Cui YF; Li PJ; Chen J; Yang C; Jiao Z
    Acta Pharmacol Sin; 2024 Oct; 45(10):2212-2225. PubMed ID: 38760542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
    Goldschmidt J; Hart L; Scott J; Boykin K; Bailey R; Heritage T; Lopez-Gonzalez L; Zhou ZY; Edwards ML; Monnette A; Ogbonnaya A; Deyoung K; Venkatasetty D; Shi P; Aton L; Huang H; Conkling PR; Gordan L
    Adv Ther; 2023 Oct; 40(10):4189-4215. PubMed ID: 37490258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trilaciclib: First Approval.
    Dhillon S
    Drugs; 2021 May; 81(7):867-874. PubMed ID: 33861388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
    Saleh MN; Patel MR; Bauer TM; Goel S; Falchook GS; Shapiro GI; Chung KY; Infante JR; Conry RM; Rabinowits G; Hong DS; Wang JS; Steidl U; Naik G; Guerlavais V; Vukovic V; Annis DA; Aivado M; Meric-Bernstam F
    Clin Cancer Res; 2021 Oct; 27(19):5236-5247. PubMed ID: 34301750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.